US4655211A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Hemostatic agent
Assignee: Unitika Ltd
•
Filing: 1985-08-08
•
Granted: 1987-04-07
•
Expires: 2005-08-08
Abstract
Abstract A hemostatic agent and method for preparation thereof are described, said hemostatic agent comprising a carrier in the shape of flake or fiber having thrombin and Factor XIII fixed thereto, wherein said carrier is composed of a biodegradable material having a water absorption capability of about 50 weight percent or more, said flake has a longer dimension of about 5000 microns or less, a shorter dimension of about 3000 microns or less, and a thickness of about 2000 microns or less, and said fiber has a single yarn fineness of about 30 deniers or less and a yarn length of about 10 mm or less.
Inventors
- 👤 Izumi Sakamoto
- 👤 Tukasa Unigame
- 👤 Kunihiko Takagi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:00
CPC Classifications
A; A61; A61L; A61L24/00; A61L24/001; A61L24/0042; A61K; A61K9/00; A61K9/14; A61K9/141; A61K9/146; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1658; A61K9/70; A61L26/00; A61L26/0061; A61L26/009; C; C12; C12N; C12N9/00; C12N9/10; C12N9/1025; C12N9/104; C12N9/1044; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6429; C12Y; C12Y304/00; C12Y304/21; C12Y304/21005; A61K38/00; A61L2400/00; A61L2400/04
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
97 words
A hemostatic agent comprising a carrier in the shape of individual, separate flake or fiber having thrombin and Factor XIII fixed thereto, wherein said carrier is composed of a biodegradable material having a water absorption capability of about 50 weight percent or more, said flake has a longer dimension of about 5,000 microns or less, a shorter dimension of about 3,000 microns or less, and a thickness of about 2,000 microns or less, and said fiber has a single yarn fineness of about 30 deniers or less and a yarn length of about 10 mm or less.
Claim 2
Dependent Claim
97 words
A hemostatic agent comprising a carrier in the shape of individual, separate flake or fiber having thrombin and Factor XIII fixed thereto, wherein said carrier is composed of a biodegradable material having a water absorption capability of about 50 weight percent or more, said flake has a longer dimension of about 5,000 microns or less, a shorter dimension of about 3,000 microns or less, and a thickness of about 2,000 microns or less, and said fiber has a single yarn fineness of about 30 deniers or less and a yarn length of about 10 mm or less.
Claim 3
Dependent Claim
37 words
A hemostatic agent as in claim 1, wherein a sol-form is provided for administration into bleeding sites by mixing with a liquid medium selected from physiological saline solution, distilled water for injection or aqueous calcium chloride solution.
Claim 4
Dependent Claim
25 words
A hemostatic agent as in claim 1, wherein said agent is usable for hemostasis at a site where bleeding is caused by puncture or biopsy.
Claim 5
Dependent Claim
18 words
A hemostatic agent as in claim 1, wherein the water absorption capability is less than 1000 weight percent.
Claim 6
Dependent Claim
36 words
A hemostatic agent as in claim 1, wherein the carrier material is selected from the grown consisting of collagen, gelatin, chitin, fibrinogen, polyglycolic acid, polylactic acid, glycolic acid-lactic acid copolymer, polyglutamic acid, amylose and oxidized amylose.
Claim 7
Dependent Claim
57 words
A hemostatic agent as in claim 1, wherein the flake has a longer dimension of 200 to 1000 microns, a shorter dimension of 200 to 800 microns, and a thickness of 800 microns or less, and the fiber has a single yarn fineness of 0.5 to 15 deniers and a yarn length of less than 3 mm.
Claim 8
Dependent Claim
43 words
A hemostatic agent as in claim 1, wherein in the use as hemostatic agent for the bleeding after biopsy in man, the amount of thrombin is 0.1 to 50000 units and the amount of Factor XIII is 0.001 to 50000 units, per injection.
Claim 9
Dependent Claim
40 words
A hemostatic agent is in claim 1, wherein the fixing amount of thrombin to the carrier is 0.001 to 1000 units per mg and the fixing amount of Factor XIII to the carrier is 0.0001 to 100 units per mg.
Claim 10
Independent Claim
120 words
A method comprising mixing a hemostatic agent with a liquid medium to obtain a sol-form, and administering said sol-form to a bleeding site, said hemostatic agent comprising a carrier in the shape of individual, separate flake or fiber having thrombin and Factor XIII fixed thereto, wherein said carrier is composed of a biodegradable material having a water absorption capability of about 50 weight percent or more, said flake has a longer dimension of about 5000 microns or less, a shorter dimension of about 3000 microns or less, and a thickness of about 2000 microns or less, and said fiber has a single yarn fineness of about 30 deniers or less and a yarn length of about 10 mm or less.
Claim 11
Independent Claim
120 words
A method comprising mixing a hemostatic agent with a liquid medium to obtain a sol-form, and administering said sol-form to a bleeding site, said hemostatic agent comprising a carrier in the shape of individual, separate flake or fiber having thrombin and Factor XIII fixed thereto, wherein said carrier is composed of a biodegradable material having a water absorption capability of about 50 weight percent or more, said flake has a longer dimension of about 5000 microns or less, a shorter dimension of about 3000 microns or less, and a thickness of about 2000 microns or less, and said fiber has a single yarn fineness of about 30 deniers or less and a yarn length of about 10 mm or less.
Claim 12
Dependent Claim
18 words
A method as in claim 9, wherein administration is performed through a puncture needle or a biopsy needle.
Claim 13
Dependent Claim
22 words
A method as in claim 9, wherein the concentration of said hemostatic agent in the sol-form is from 5 to 500 mg/ml.
Claim 14
Dependent Claim
19 words
A method as in claim 9, wherein the amount of hemostatic agent per injection is 1 to 5000 mg.
References Cited (Backward Citations)
US2533004A
Cited
US3249109A
Cited
US3419006A
Cited
DE2914822A1
Cited
US4265233A
Cited
US4271070A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-04-06 | 1990-10-06 | 1991-04-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-04-06 | 1994-10-06 | 1995-04-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-04-06 | 1998-10-06 | 1999-04-07 | $7700.00 | Window Closed / Lapsed |